tailieuchung - Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France

Đang chuẩn bị liên kết để tải về tài liệu:
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France

Yến Hồng 28 9 pdf

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ Tải xuống

COU-AA-301 trial has proved that abiraterone acetate (AA), a selective inhibitor of androgen biosynthesis, improved overall survival (OS) of patients with metastatic castration resistant prostate cancer (mCRPC) after a first line of docetaxel. Based on this result, a Temporary Authorization for Use (TAU) was performed between December 2010 and July 2011 to provide patients with mCRPC the opportunity to receive AA before its commercialization. |

Đang chuẩn bị liên kết để tải về tài liệu:
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France

The LACOG-0415 phase II trial: Abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: Results from a prospective observational study (CAPRO)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter “real life” study

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castrationresistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

Đánh giá kết quả điều trị Abiraterone Acetate + Prednisolon ung thư tuyến tiền liệt di căn kháng cắt tinh hoàn

Abiraterone acetate plus prednisone for the Management of Metastatic CastrationResistant Prostate Cancer (mCRPC) without prior use of chemotherapy: Report from a large, international, real-world retrospective cohort study

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France

Corticosteroid switch from prednisone to dexamethasone in metastatic castrationresistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer

Đang chuẩn bị liên kết để tải về tài liệu: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France